Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial

Lorinda Chung, Cathie Spino, Richard McLain, Sindhu R. Johnson, Christopher P. Denton, Jerry A. Molitor, Virginia D. Steen, Robert Lafyatis, Robert W. Simms, Suzanne Kafaja, Tracy M. Frech, Vivien Hsu, Robyn T. Domsic, Janet E. Pope, Jessica K. Gordon, Maureen D. Mayes, Nora Sandorfi, Faye N. Hant, Elana J. Bernstein, Soumya ChatterjeeFlavia V. Castelino, Ali Ajam, Yannick Allanore, Marco Matucci-Cerinic, Michael L. Whitfield, Oliver Distler, Ora Singer, Amber Young, Vivek Nagaraja, David A. Fox, Daniel E. Furst, Dinesh Khanna

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial'. Together they form a unique fingerprint.

Medicine & Life Sciences